Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences

TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.

Oppenheimer 15th Annual Israeli Investor Conference
Date: Sunday, May 11, 2014
Time: 7:10am Eastern/1:10pm GMT +2
Location: David Intercontinental Hotel in Tel-Aviv
MIXiii/BioMed Israel Innovation Conference
Date: Wednesday, May 21, 2014
Panel Title: "Riding the IPO Wave"
Time: 9am Eastern/3pm GMT +2
Company Presentation 11am Eastern/5pm GMT +2
Location: Tel-Aviv Fairgrounds

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts: LifeSci Advisors, LLC Michael Rice 646-597-6979 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.